Edgar Filing: CORE LABORATORIES N V - Form 10-Q

CORE LABORATORIES N V Form 10-Q October 22, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

<i>~</i>		_	
(M	lark	()r	ıe)

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2009

OR

" TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _____

Commission File Number: 001-14273

CORE LABORATORIES N.V.

(Exact name of registrant as specified in its charter)

The Netherlands (State of other jurisdiction of incorporation or organization) Not Applicable (I.R.S. Employer Identification No.)

Herengracht 424 1017 BZ Amsterdam The Netherlands (Address of principal executive offices)

Not Applicable (Zip Code)

(31-20) 420-3191 (Registrant's telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes "No"

Edgar Filing: CORE LABORATORIES N V - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ý Accelerated filer " Non-accelerated filer " Smaller reporting company " (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes "No ý

The number of common shares of the registrant, par value EUR 0.04 per share, outstanding at October 21, 2009 was 22,981,112.

${\it CORE\ LABORATORIES\ N.V.}$ FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2009

INDEX

		Page
	PART I - FINANCIAL INFORMATION	
Item 1.	Financial Statements	
	Consolidated Balance Sheets (Unaudited) at September 30, 2009 and December 31, 2008	1
	Consolidated Statements of Operations (Unaudited) for the Three Months Ended September 30, 2009 and 2008	2
	Consolidated Statements of Operations (Unaudited) for the Nine Months Ended September 30, 2009 and 2008	3
	Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2009 and 2008	4
	Notes to the Unaudited Consolidated Interim Financial Statements	5
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27
	PART II - OTHER INFORMATION	
Item 1.	<u>Legal Proceedings</u>	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 6.	<u>Exhibits</u>	29
	<u>Signature</u>	30

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

and 22,980,612 outstanding at 2009

CORE LABORATORIES N.V. CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

	S	eptember 30, 2009		ecember 31, 2008
ASSETS	(Unaudited)			
CURRENT ASSETS:				
Cash and cash equivalents	\$	137,225	\$	36,138
Accounts receivable, net of allowance for doubtful				
accounts of \$4,544 and				
\$3,535 at 2009 and 2008, respectively		117,981		144,293
Inventories, net		34,317		34,838
Prepaid expenses and other current assets		18,759		20,376
TOTAL CURRENT ASSETS		308,282		235,645
PROPERTY, PLANT AND EQUIPMENT, net		97,966		103,463
INTANGIBLES, net		6,637		6,992
GOODWILL		148,600		148,600
DEFERRED TAX ASSET		17,123		17,708
OTHER ASSETS		12,191		9,127
TOTAL ASSETS	\$	590,799	\$	521,535
LIABILITIES AND EQUITY				
CURRENT LIABILITIES:				
Accounts payable	\$	27,981	\$	41,588
Accrued payroll and related costs		25,174		28,637
Taxes other than payroll and income		7,766		7,949
Unearned revenues		6,615		7,932
Income tax payable		7,140		-
Other accrued expenses		10,938		9,584
TOTAL CURRENT LIABILITIES		85,614		95,690
LONG-TERM DEBT		205,377		194,568
DEFERRED COMPENSATION		16,124		12,815
OTHER LONG-TERM LIABILITIES		33,625		30,177
COMMITMENTS AND CONTINGENCIES				
EQUITY:				
Preference shares, EUR 0.04 par value;				
3,000,000 shares authorized, none issued or				
outstanding		-		-
Common shares, EUR 0.04 par value;				
100,000,000 shares authorized, 25,519,956 issued				

Edgar Filing: CORE LABORATORIES N V - Form 10-Q

and 25,519,956 issued and 23,020,033 outstanding a	at				
2008		1,430		1,430	
Additional paid-in capital		50,134		53,019	
Retained earnings		448,136		382,266	
Accumulated other comprehensive (loss)		(4,751)	(4,927)
Treasury shares (at cost), 2,539,344 at 2009 and					
2,499,923 at 2008		(247,133)	(245,661)
Total Core Laboratories N.V. shareholders'					
equity		247,816		186,127	
Non-controlling interest		2,243		2,158	
TOTAL EQUITY		250,059		188,285	
TOTAL LIABILITIES AND EQUITY	\$	590,799		\$ 521,535	

The accompanying notes are an integral part of these consolidated financial statements.

Return to index

Edgar Filing: CORE LABORATORIES N V - Form 10-Q

CORE LABORATORIES N.V. CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Three Months Ended September 30, 2009 2008		
	(Unaudited)		
REVENUES:			
Services	\$ 133,819	\$	154,297
Product sales	33,983		48,226
	167,802		202,523
OPERATING EXPENSES:			
Cost of services, exclusive of depreciation expense			
shown below	85,792		100,264
Cost of product sales, exclusive of depreciation			
expense shown below	26,383		33,941
General and administrative expenses	6,637		6,857
Depreciation	5,840		5,355
Amortization			